Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
NCT05071482 · Institute of Hematology & Blood Diseases Hospital, China · PHASE4 · terminated · last registry update 2025-05-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “terminated” | – | Registry record, Institute of Hematology & Blood Diseases Hospital, China |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-27Also stopped (terminated): M.D. Anderson Cancer Center, Ponatinib + Venetoclax (NCT05268003)
- 2026-04-15Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Tofacitinib + Imatinib (NCT07530367)
- 2026-04-03Results posted on the registry: Georgetown University, Placebo oral capsule + Nilotinib Oral Capsule (NCT04002674)
- 2026-04-01Results posted on the registry: University of North Carolina, Chapel Hill, MCT + Clazakizumab (NCT04129931)
- 2026-03-25Results posted on the registry: University of Maryland, Baltimore, Imatinib + Placebo oral tablet (NCT04394416)
- 2026-03-25Also stopped (terminated): University of Maryland, Baltimore, Imatinib + Placebo oral tablet (NCT04394416)
- 2026-03-19Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., TQB2102 Injection + Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets (NCT07483684)
- 2026-03-13Also stopped (terminated): Centre Oscar Lambret, Imatinib (NCT00421317)
- 2026-03-11Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07137390)
- 2026-03-09Also stopped (terminated): Translational Research in Oncology, Regorafenib in combination with pembrolizumab (NCT04777851)
- 2026-03-05Results posted on the registry: Wake Forest University Health Sciences, Regorafenib (NCT04327700)
- 2026-03-05Also stopped (terminated): Wake Forest University Health Sciences, Regorafenib (NCT04327700)
- 2026-03-02Also stopped (terminated): M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2026-02-27Results posted on the registry: Massachusetts General Hospital, Umbralisib + Rituximab (NCT03919175)
- 2026-02-27Also stopped (terminated): Massachusetts General Hospital, Umbralisib + Rituximab (NCT03919175)
- 2026-02-25Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07223567)
- 2026-02-06Phase 3 first posted: Nanjing Sanhome Pharmaceutical, Co., Ltd., SH006 + Bevacizumab (NCT07392866)
- 2026-02-03Phase 3 first posted: Shanghai JMT-Bio Inc., JSKN003 + Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (NCT07384377)
- 2026-01-30Phase 3 first posted: Ningbo Newbay Technology Development Co., Ltd, NB003 + regorafenib (NCT07379047)
- 2026-01-29Results posted on the registry: Indiana University, Imatinib Mesylate (NCT03997903)
- 2026-01-29Also stopped (terminated): Indiana University, Imatinib Mesylate (NCT03997903)
- 2026-01-20Results posted on the registry: Novartis Pharmaceuticals, Nilotinib (NCT00756509)
- 2026-01-20Results posted on the registry: Bristol-Myers Squibb, BMS-986288 + Nivolumab (NCT03994601)
- 2026-01-20Also stopped (terminated): Anwaar Saeed, Regorafenib + Pembrolizumab (NCT06006923)
- 2026-01-15Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib (NCT00254423)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision